Why I’d buy these 2 FTSE 100 defensive shares today

I think holding FTSE 100 defensives in my investing portfolio is always a good idea. It can keep me safe in times of economic downturns. 

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

It is not like I am expecting a recession or even a slowdown. But I do think that it is a good idea to allocate a proportion of my stock investing portfolio to FTSE 100 defensives or safe shares. 

Why buy FTSE 100 defensives

The reason is that economic growth happens in cycles. This means that we should always be prepared for the next phase, and that includes downturns. Moreover, sometimes these come about unpredictably, as we saw last year. 

The FTSE 100 index has a number of high-quality defensives to choose from, ranging across sectors from healthcare to technology, that I can choose from today. Here are two of them:

#1. Hikma Pharmaceuticals: robust health

After touching all-time highs in October, drug manufacturer Hikma Pharmaceuticals (LSE: HIK) has now seen a share price fall of 18%. But going by its results, I think that the manufacturer of Covid-19 medication is due for another share price rally. 

For the full year 2020, the company saw a 23% increase in operating profit and its revenues increased as well. It expects to continue making progress in 2021 too. 

A small positive in buying the share is also its dividend payouts. It has a yield of 1.6%, but it is increasing its dividends. 

The flipside here is that its reported earnings per share (EPS) fell by 9% in the year. To me, this makes further increases in dividends unlikely.

Also, I think this FTSE 100 share could take its time to start rising from here. Defensives or safe stocks are less attractive to investors now, as the economic outlook improves. For the long-term, though, it is a buy for me. 

#2. Unilever: back to market crash levels

The consumer staples’ giant Unilever (LSE: ULVR) saw a sharp share price fall early last month after it reported an underwhelming set of financials. Both the company’s revenues and profits fell.

Going by the company’s past resilience however, I see this more as a blip than the start of a trend. This is even more so now that the economy will recover in 2021. 

Importantly, for income investors the 1% decline in its EPS was disappointing too. The Unilever stock did not have a high dividend yield in the past. But after the hit to dividends across the board in 2020, it does look relatively more attractive from the income perspective. It has a yield of 3.6% now, which I think is alright compared to many others. 

The risk to Unilever is that of a slow recovery or if cost pressures mount.

Another poor year for the UK’s consumer giant will tell further on its share price. Investors have made their disappointment with the latest results amply clear already. In the weeks following the results, its share price dropped to the levels seen during last year’s stock market crash. 

The FTSE 100 share has started recovering since, and I am optimistic about its prospects on balance. 

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »